Semaglutide is typically given once a week, while tirzepatide is also given as a weekly injection. Semaglutide has been shown to significantly lower HbA1c (a measure of long-term blood sugar control) and promote weight loss
It is important to remember that individual responses to medication can vary, and what works for one person may not work for another
The economic and human costs of prevention pale compared to managing established disease for decades
In clinical trials of SGLT2 inhibitors in type 2 diabetes, discontinuation rates among those receiving active treatment have been less variable, ranging from 21% during a median follow-up time of 50 months in the DECLARE-TIMI 58 trial of dapagliflozin to 29% during a mean follow-up time of 43 months in the CANVAS trial of canagliflozin [14,15,16,17,18]
This layer is thin, typically 1 to 3 millimeters